1. Argani, P . MiT family translocation renal cell carcinoma. Semin. Diagn. Pathol 2015; 32: 103–113.
Google Scholar | Crossref | Medline2. Caliò, A, Segala, D, Munari, E, et al. MiT family translocation renal cell carcinoma: from the early descriptions to the current Knowledge. Cancers (Basel) 2019; 11: 1110.
Google Scholar | Crossref | Medline3. Edge, SB, Compton, CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471–1474.
Google Scholar | Crossref | Medline4. Linee Guida AIOM 2019: tumori del rene , https://www.aiom.it/wp-content/uploads/2019/10/2019_LG_AIOM_Rene.pdf
Google Scholar5. Motzer, RJ, Jonasch, E, Boyle, S, et al. NCCN guidelines insights: kidney cancer, version 1.2021. J Natl Compr Cancer Netw 2020; 18.
Google Scholar6. Moch, H, Cubilla, AL, Humphrey, PA, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs: part a: renal, penile, and testicular tumours. Eur Urol 2016; 70: 93–105.
Google Scholar | Crossref | Medline7. de Jong, B, Molenaar, IM, Leeuw, JA, et al. Cytogenetics of a renal adenocarcinoma in a 2-year-old child. Cancer genetics and cytogenetics 1986; 21: 165–169.
Google Scholar | Crossref | Medline8. Lopez-Beltran, A, Scarpelli, M, Montironi, R, et al. 2004 WHO classification of the renal tumors of the adults. Eur Urol 2006; 49: 798-805.
Google Scholar | Crossref | Medline9. Caliò, A, Brunelli, M, Segala, D, et al. Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets. Pathology 2020; 52: 297-309.
Google Scholar | Crossref | Medline10. Tsuda, M, Davis, IJ, Argani, P, et al. Cancer Res 2007; 67: 919-929.
Google Scholar | Crossref | Medline11. Choueiri, TK, Lim, ZD, Hirsch, MS, et al. Vascular endothelial growth factor-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer 2010; 116: 5219-5225.
Google Scholar | Crossref | Medline12. Malouf, GG, Camparo, P, Oudard, S, et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol 2010; 21: 1834–1838.
Google Scholar | Crossref | Medline13. Martínez Chanzá, N, Xie, W, Asim Bilen, M, et al. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncol 2019; 20: 581–590.
Google Scholar | Crossref | Medline14. Boilève, A, Carlo, MI, Barthélémy, P, et al. Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders. J Immunother Cancer 2018; 6: 159.
Google Scholar | Crossref | Medline15. Koshkin, VS, Barata, PC, Zhang, T, et al. Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. J Immunother Cancer 2018; 6: 9.
Google Scholar | Crossref | Medline